### United Republic of Tanzania

**Population 2018**: 56 million

**Tuberculosis profile**

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>142 (67–245)</td>
<td>253 (119–435)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>40 (19–69)</td>
<td>71 (34–122)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>1.9 (0.67–3.7)</td>
<td>3.3 (1.2–6.6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>22 (10–40)</td>
<td>40 (16–70)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>16 (7.8–27)</td>
<td>29 (14–49)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 0.97% (0.4–1.6)
- Previously treated cases: 13% (11–15)

**TB case notifications, 2018**

- Total new and relapse: 74 692
  - % tested with rapid diagnostics at time of diagnosis: 18%
  - % with known HIV status: 99%
  - % pulmonary: 79%
  - % bacteriologically confirmed**: 48%
  - % children aged 0-14 years: 14%
  - % women: 33%
  - % men: 53%

- Total cases notified: 75 828

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 53% (30–110)
- TB patients facing catastrophic total costs: 30% (11–53)
- HIV-negative TB mortality: 22 (10–40)
- HIV-positive TB mortality: 16 (7.8–27)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 70%
  - New cases: 70%
  - Previously treated cases: 81%

**Laboratory-confirmed cases**

- Patients on ART: 20 695 (28%)
- Patients on ART and on antiretroviral therapy: 20 337 (98%)

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017: 90% 68 278
- Previously treated cases, excluding relapse, registered in 2017: 84% 1 250
- HIV-positive TB cases registered in 2017: 80% 21 349
- MDR/RR-TB cases started on second-line treatment in 2016: 80% 158
- XDR-TB cases started on second-line treatment in 2016: 0

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 22% (20–24)

**TB financing, 2019**

- National TB budget (US$ millions): 62
  - Funding source: 4% domestic, 24% international, 72% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only

Data are as reported to WHO. Estimates of TB and MDR burden are produced by WHO in consultation with countries.
Generated: 2019-11-20
Data: www.who.int/tb/data